Cite
Targeting the immune-privileged myofibroblast in oral submucous fibrosis by CAR T-cell therapy.
MLA
Sarode, Sachin C., et al. “Targeting the Immune-Privileged Myofibroblast in Oral Submucous Fibrosis by CAR T-Cell Therapy.” Medical Hypotheses, vol. 165, Aug. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.mehy.2022.110897.
APA
Sarode, S. C., Sharma, N. K., Sarode, G., Sharma, M., & Radhakrishnan, R. (2022). Targeting the immune-privileged myofibroblast in oral submucous fibrosis by CAR T-cell therapy. Medical Hypotheses, 165, N.PAG. https://doi.org/10.1016/j.mehy.2022.110897
Chicago
Sarode, Sachin C., Nilesh Kumar Sharma, Gargi Sarode, Mohit Sharma, and Raghu Radhakrishnan. 2022. “Targeting the Immune-Privileged Myofibroblast in Oral Submucous Fibrosis by CAR T-Cell Therapy.” Medical Hypotheses 165 (August): N.PAG. doi:10.1016/j.mehy.2022.110897.